Publisher Correction: BMC Infectious Diseases (2022) 22:793 https://doi.org/10.1186/s12879-022-07774-9

In the original publication of this article [1] the footnotes of Figure 1 were accidentally omitted during the publication process. In this correction article: Fig. 1 with the footnotes is published. The original article has been updated to rectify this error. The publisher apologizes to the authors and readers for the inconvenience caused.

Fig. 1
figure 1

Flow chart of drugs prescription choices according to risk of progression of COVID-19. *Presence of at least one of the following factors: age > 65 years, BMI ≥ 30, patients chronically subjected to peritoneal dialysis or haemodialysis, uncontrolled diabetes mellitus or with chronic complications, primitive or secondary immunodeficiency (particularly concerning patients being treated with immunosuppressive drugs or less than 6 months from suspension of treatment), cardiocerebrovascular disease (including arterial hypertension with organ damage), COPD and/or other chronic respiratory diseases (lung fibrosis or patient needing O2-therapy for reasons different from SARS-CoV-2 infection), active oncological or oncohematological disease, chronic hepatopathy, hemoglobinopathies, neurodegenerative disorders. 1Patients affected by haematological malignancies/autoimmune diseases or treated with immunosuppressive drugs or transplant receivers; 2First choice in patients with eGFR > 30 ml/min and no major drug interactions; 3Useful in patients with eGFR > 30 ml/min if major drug interactions contraindicate nirmatrelvir/ritonavir or in patients with dysphagia; 4For use in patients with severe renal insufficiency and/or partially immunised (i.e., previous SARS-CoV-2 infection, vaccination course incomplete or completed more than 6 months before); 5mAbs therapy was chosen considering local epidemiology of variants of concern

Full size image